Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris N Barnes

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2020
Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major MetaboliteDavid L Bourdet, Suresh Yeola, Sharath S Hegde, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|October 25, 2019
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow RateDonald A Mahler, Jill A Ohar, Chris N Barnes, et al.
Drugs - Real World Outcomes|November 8, 2019
Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)Adam M Bressler, Ali A Hassoun, Louis D Saravolatz, et al.
Alimentary Pharmacology & Therapeutics|April 3, 2021
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 studyBraden Kuo, Chris N Barnes, Deanna D Nguyen, et al.
Data in Brief|September 20, 2019
Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary diseaseJames Donohue, Edward Kerwin, Sanjay Sethi, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 12, 2019
Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical TrialsGary T Ferguson, Gregory Feldman, Krishna K Pudi, et al.
Respiratory Medicine|June 1, 2019
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseJames F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Respiratory Research|November 1, 2019
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)James F Donohue, Edward Kerwin, Sanjay Sethi, et al.
The Journal of Clinical Endocrinology and Metabolism|June 19, 2021
Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 StudiesKyriakie Sarafoglou, Chris N Barnes, Michael Huang, et al.
Neurogastroenterology and Motility|January 10, 2023
A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesisThomas L Abell, Braden Kuo, Tuba Esfandyari, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2020
Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major MetaboliteDavid L Bourdet, Suresh Yeola, Sharath S Hegde, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|October 25, 2019
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow RateDonald A Mahler, Jill A Ohar, Chris N Barnes, et al.
Drugs - Real World Outcomes|November 8, 2019
Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)Adam M Bressler, Ali A Hassoun, Louis D Saravolatz, et al.
Alimentary Pharmacology & Therapeutics|April 3, 2021
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 studyBraden Kuo, Chris N Barnes, Deanna D Nguyen, et al.
Data in Brief|September 20, 2019
Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary diseaseJames Donohue, Edward Kerwin, Sanjay Sethi, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 12, 2019
Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical TrialsGary T Ferguson, Gregory Feldman, Krishna K Pudi, et al.
Respiratory Medicine|June 1, 2019
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseJames F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Respiratory Research|November 1, 2019
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)James F Donohue, Edward Kerwin, Sanjay Sethi, et al.
The Journal of Clinical Endocrinology and Metabolism|June 19, 2021
Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 StudiesKyriakie Sarafoglou, Chris N Barnes, Michael Huang, et al.
Neurogastroenterology and Motility|January 10, 2023
A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesisThomas L Abell, Braden Kuo, Tuba Esfandyari, et al.
Pageof 3